Grace Opens GMP Release QC Lab at Oregon Facility
News Aug 19, 2016
W. R. Grace & Co. has announced the opening of a Good Manufacturing Practice (GMP) release Quality Control (QC) lab at its fine chemicals manufacturing facility located in Albany, Oregon, expanding support for GMP manufacturing and release for the pharmaceutical and dietary-related industries. The new lab’s capabilities will enable the site to validate analytical methods and perform GMP release of starting materials and advanced intermediates.
The lab already has passed customer inspections and completed method validation and GMP release of commercial intermediates for major pharmaceutical companies. The analytical equipment in the lab includes HPLC, UPLC, GC-MS, and GC-MS with head space, along with other common analytical equipment.
“Grace continues to invest and expand our capabilities in custom manufacturing of regulatory materials,” said Brett Reynolds, Global Business Director for Fine Chemicals. “This higher level GMP manufacturing expands our portfolio of products and services to the pharmaceutical and related industries.”
Grace acquired the Albany facility from Synthetech, Inc. in 2010. The Albany site’s operations team has more than 30 years of custom manufacturing experience in multi-step organic, organometallic, and chiral chemistry, and integrated kilos-to-tons GMP production.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018